Department of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
Axitinib, an oral small-molecule tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma. Common side effects include hypertension, fatigue and dysphonia. Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma. Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.
Written by:
Ho TH, Jonasch E. Are you the author?
Reference: Future Oncol. 2011 Nov;7(11):1247-53.
doi: 10.2217/fon.11.107
PubMed Abstract
PMID: 22044199
UroToday.com Renal Cancer Section
